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A recent article in Toxicology Reports by Rebholz et al. [26]
eported increased plasma cholesterol levels (primarily as HDL) in
57BL/6 (male and female) and BALB/c (male only) mice given high
at (Westernized) diet which also contained PFOA. The authors con-
luded that PFOA ingestion leads to hypercholesterolemia and they
tated these data were “consistent with human observational ﬁnd-
ngs”. There are several key factors which have not been considered
n their study and we offer this letter to identify this important
nformation. In particular, we feel that this conclusion needs more
alance, particularly with respect to the relevance and translata-
ility of their ﬁndings to the human situation.
. Difference in lipoprotein metabolism and responsiveness
o hypolipidemic drugs between humans and mice
Conventional mouse strains used in preclinical biomedical and
oxicological research, including the C57BL/6 mice and BALB/c
ice studied by Rebholz et al., are considered not to be the most
ppropriate animal models to study modulation of lipoprotein
etabolism, since lipolysis of TG-rich particles as chylomicrons
nd very low density lipoprotein (VLDL) and their remnants and
learance of the apoB-containing (non-HDL) lipoproteins via the
polipoproteinE-LDL-receptor (apoE-LDLR) pathway are fast pro-
esses as compared to humans [6]. Consequently, the mice have
elatively low plasma TG and cholesterol levels with low levels of
he atherogenic VLDL and LDL, and the majority of cholesterol is
ontained in HDL (Fig. 1A,B). Severe dietary regimens with sat-
rated fat and high amounts of cholesterol and cholic acid are
equired to increase the amount of non-HDL-C to some extent, but
till lower than in humans [25].
In contrast in humans, lipolysis is slower and removal of
poB-containing lipoproteins is delayed [6]. In addition, humans
nlike mice possess an important player in lipoprotein metabolism,
holesterol ester transfer protein (CETP), which transfers choles-
erol from HDL to (V)LDL in exchange for triglycerides, thereby
ncreasing (V)LDL-C levels and decreasing HDL-C. Due to these dif-
ttp://dx.doi.org/10.1016/j.toxrep.2016.02.002
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access 
y-nc-nd/4.0/).ferences, cholesterol is contained mainly in LDL and to a lesser
extent in HDL (Fig. 1C,D).
2. A translational mouse model that closely mimics human
lipoprotein metabolism is available
To develop a mouse model with a more human-like lipopro-
tein metabolism for pharmacological and toxicological research,
the APOE*3-Leiden transgenic mouse was  generated by the
introduction of a genomic human DNA construct carrying the
mutant APOE*3-Leiden gene, the APOCI gene, and all known
regulatory elements, obtained from a patient with Familial Dys-
betalipoproteinemia (FD) [23]. These mice were cross-bred with
mice expressing human CETP under control of its natural ﬂanking
regulatory DNA-sequences [12] to obtain the APOE*3-Leiden.CETP
mouse, as a humanized model for FD and mixed dyslipoproteinemia
[29]. While normal wild-type mice have a very rapid clearance of
apoB-containing lipoproteins, APOE*3-Leiden(.CETP) mice have an
impaired clearance and increased TG level, and are thereby mimick-
ing the slow clearance observed in humans, particularly in patients
with FD [6,28,15]. Importantly, as compared to the widely used
hyperlipidemic and atherogenic apoE- and LDLR-deﬁcient (E0/0
and LDLR0/0) mice, the APOE*3-Leiden(.CETP) mice possess an
intact but delayed apoE-LDLR-mediated clearance, which is essen-
tial for the proper, human-like response on hypolipidemic drugs
[1]. APOE*3-Leiden.CETP mice respond well to dietary interven-
tion using human-relevant (Westernized) diets with increases in
plasma cholesterol and TG and these lipids can be titrated to levels
mimicking those in humans.
As background, FD or type III hyperlipoproteinemia is character-
ized by elevated levels of plasma cholesterol and an increased
ratio of cholesterol to TG in the VLDL and intermediate-
density lipoprotein (IDL) fractions, resulting in the appearance
of -VLDL particles ([15]). Similarly as in FD patients, in APOE*3-
Leiden and APOE*3-Leiden.CETP mice the major part of plasma
cholesterol is contained in the VLDL and VLDL-remnant parti-
cles, leading to formation of -VLDL particles, which is further
increased by cholesterol feeding [23,29] (Fig. 1E,F).
With respect to response to hypolidemic drugs and contrary to
wildtype or E0/0 and LDLR0/0 mice and other species [17], the
APOE*3-Leiden(.CETP) mice respond in a similar way to statins
as humans do, both with respect to direction and magnitude of
the change with decreases in the apoB-containing lipoproteins
up to 55% ([5,14,8]). In addition, the extent of lipid-lowering and
change in lipoprotein proﬁle observed with ﬁbrates ([16,10,9]),
niacin ([11,18,9]) and the new anti-PCSK9 therapy with mon-
oclonal antibodies ([19,1]) in APOE*3Leiden(.CETP) mice is
comparable to that of hyperlipidemic and FD patients.
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Fig. 1. Mice have a fast clearance of apoB-containing lipoproteins and do not express CETP (A), as a result the majority of plasma cholesterol is conﬁned to HDL  (B), with TC
and  TG levels of 1.5–2.0 and 0.2–0.3 mmol/L in C57BL/6 mice. Humans have a slower clearance of apoB-containing lipoproteins and do express CETP (C) and normolipidemic
m l cons
a  to tha
m
3
a
m
r
A
n
a
tan  have TC and TG levels of <5.2 and 0.5–1.5 mmol/L, respectively, and cholestero
 lipoprotein proﬁle similar as in FD patients and a lipoprotein metabolism similar
ainly  conﬁned to the non-HDL-C fraction (F).
. Effect of PFOA on lipoprotein metabolism in relevant
nimal models and human clinical study
To explore the effects of PFOA on lipoprotein metabolism in this
ouse model, we recently started to investigate the effects of envi-
onmentally and occupationally relevant PFOA exposure in male
POE*3-Leiden.CETP mice fed a Western-type diet. Our prelimi-
ary data showed that dietary intake of PFOA reduced plasma TG
nd cholesterol levels with the cholesterol reduction conﬁned to
he apoB-containing (non-HDL-C) lipoproteins.ists mainly of non-HDL-C (VLDL-C/LDL-C) (D). The APOE*3-Leiden.CETP mouse has
t in man  (E), and on a chow diet TC and TG levels are 3.0–4.0 and 2.5–3.0 mmol/L,
In support of the translatability of the APOE*3-Leiden.CETP
mouse for investigation of the mechanistic background of alter-
ations in lipid and lipoprotein metabolism, the reduction in
non-HDL-C found in our study as well as data reported by Loveless
et al. [22] is consistent with results from a phase I trial with PFOA in
humans. In that study, 41 cancer patients were given ammonium
PFOA doses of up to 1200 mg/week for a median of 6.5 weeks, which
resulted in a reduction of non-HDL-C as a treatment effect [24].
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. Non-HDL-C/LDL-C-lowering versus HDL-C-raising on
ardiovascular risk in clinical outcome studies and relevant
nimal models
The increase of plasma cholesterol reported by Rebholz et al.,
as conﬁned to HDL-C, whereas we and others found a decrease
n (V)LDL-C (non-HDL-C) after PFOA exposure. The question then
rises how these alterations in lipoprotein metabolism translate
nto cardiovascular risk. LDL-C is recognized as a primary causal
isk factor in cardiovascular disease as evidenced from many exper-
mental, epidemiological and genetic studies [27]. In addition,
ntervention trials with statin therapy conﬁrm a reduced incidence
f coronary heart disease as a consequence of cholesterol-lowering
n LDL [2,21] and recent trials indicate that intensive lipid-lowering
ith statins may  be more beneﬁcial in risk reduction than less
ntensive (or standard) therapy [3]. According to results from the
atter meta-analysis, every 1 mmol/L (40 mg/dL) reduction in LDL-
 is associated with a 22% reduction in the risk of major vascular
vents suggesting that a 2–3 mmol/L reduction in LDL-C would cor-
espond with a 40–50% reduction in events.
Epidemiological studies consistently report an inverse associa-
ion between coronary heart disease risk and HDL-C: Results from
 prospective epidemiologic studies indicate that an increase of
 mg/dL (0.03 mM)  in HDL-C is associated with a 2–3% reduction in
isk [7].
Besides its major role in reverse cholesterol transport, HDL
as also been described to have anti-inﬂammatory, anti-oxidant,
nti-platelet and vasodilatory properties and may  therefore have
 protective role in coronary heart disease [13]. Several thera-
eutic approaches aimed at raising HDL-C levels have since been
nvestigated. However, undisputed proof for causality of low HDL-
 in cardiovascular disease is lacking and clinical trials aimed
t raising HDL-C to prevent disease (AIM-HIGH, HPS2-THRIVE,
al-OUTCOMES) have failed to meet their primary goals [13]. In
ddition, data from Mendelian randomization studies show that
DL-C and myocardial infarction risk are not causally related [13].
For a systematic review and meta-analysis of relevant
reclinical studies and clinical trials on the contribution of non-
DL-C/LDL-C-lowering versus HDL-C-raising we refer to Kühnast
t al. [20]. In this review we investigated the effects of established
nd novel treatment strategies, speciﬁcally targeting HDL, on inhi-
ition of atherosclerosis development in CETP-expressing animals,
ince CETP is a crucial gene involved in HDL-C metabolism and
mplicated in the mechanisms by which most therapies modulate
DL-C [4]. In addition, we conducted a meta-analysis to evaluate
he potential effects of these treatment strategies on the prevention
f clinical events in randomized controlled trials, focusing specif-
cally on the contribution of non-HDL-C/LDL-C-lowering versus
DL-C-raising. We  conclude that the protective role of lowering
DL-C and non-HDL-C is well-established. The contribution of rais-
ng HDL-C on inhibition of atherosclerosis and the prevention of
ardiovascular disease remains undeﬁned and may  be dependent
n the mode of action of HDL-C-modiﬁcation. Similar outcome data
ere found for the prevention of clinical events in randomized
ontrolled trials and on inhibition of atherosclerosis in relevant,
ETP-expressing, animals emphasizing the validity/translatability
f these animal models to the human situation [20].
. Concluding remarks
Rebholz et al. conclude “To summarize, we have shown that
57BL/6 and male BALB/c mice exposed to PFOA have signiﬁcantly
ncreased plasma cholesterol levels when fed Westernized diets,
onsistent with human observational ﬁndings at the national [refs
9,14 therein] and community levels [refs 16,19,60 therein] and
[eports 3 (2016) 306–309
in adolescent [refs 18,20 therein] and occupational [refs 44,56,57,9
therein] cohorts”. As discussed above, there are a number of issues
with the outcome of their study and extrapolation of the data from
a study in wildtype mice to the human situation. The choice of the
mouse model should be carefully considered, given its inherent dif-
ferences in lipoprotein metabolism and distribution of cholesterol
among lipoproteins between wildtype mice and man, as well as
the differences in changes in lipoproteins induced by PFOA and the
potential cardiovascular risk raised by these changes. For all the
reasons articulated above we felt it is premature for Rebholz et al.
to conclude that PFOA causes hypercholesterolemia in these mice
fed Westernized diets.
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